Testing engineered immune cells for H3K27M diffuse midline glioma and DIPG
Official title: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests immune cells built to target a tumor change called H3K27M.
Read our full plain-language summary
What the trial team says
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Key facts
- Registry number
- NCT07501156
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Where it is running
This trial lists 1 site.
-
Guangdong
- Shenzhen Geno-immune Medical Institute (Shenzhen)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.